Overview

Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients

Status:
Suspended
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Prophylactic treatment will start from surgery until the patients are discharged from the hospital(18). Then each patient will have 2 follow up visit in gyne- oncology clinic. The first visit will be 2 weeks from discharge & the second visit will be 3 months after surgery. In each visit patient will be evaluated for any evidence of thrombo-embolic events clinically & radiologically if needed ( spiral CT, V/Q scan & lower limp Doppler ). Any side effect or adverse reaction will be reported & it will be evaluated if it is related to the drug used or not.
Phase:
Phase 3
Details
Lead Sponsor:
National Guard Health Affairs
Treatments:
Calcium heparin
Dalteparin
Enoxaparin
Heparin
Heparin, Low-Molecular-Weight